N-[[1-(2-methyl-5-phenyl-1,3-thiazole-4-carbonyl)-5-oxopiperidin-2-yl]methyl]quinoline-8-carboxamide | 1396764-59-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[[1-(2-methyl-5-phenyl-1,3-thiazole-4-carbonyl)-5-oxopiperidin-2-yl]methyl]quinoline-8-carboxamide
• CAS: 1396764-59-2
• 化学式: C₂₇H₂₄N₄O₃S
• 分子量: 484.579
• InChiKey: CPSGHCXFCJWMLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[[1-(2-methyl-5-phenyl-1,3-thiazole-4-carbonyl)-5-oxopiperidin-2-yl]methyl]quinoline-8-carboxamide 在 氨 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists

  摘要：

  A series of orexin receptor antagonists was synthesized based on a substituted piperidine scaffold. Through traditional medicinal chemistry structure-activity relationships (SAR), installation of various groups at the 3-6-positions of the piperidine led to modest enhancement in receptor selectivity. Compounds were profiled in vivo for plasma and brain levels in order to identify candidates suitable for efficacy in a model of drug addiction. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.122
• 作为产物：
  描述：

  (2-(aminomethyl)-5-ethoxypiperidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基乙酰胺 为溶剂， 生成 N-[[1-(2-methyl-5-phenyl-1,3-thiazole-4-carbonyl)-5-oxopiperidin-2-yl]methyl]quinoline-8-carboxamide
  参考文献：
  名称：

  Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists

  摘要：

  A series of orexin receptor antagonists was synthesized based on a substituted piperidine scaffold. Through traditional medicinal chemistry structure-activity relationships (SAR), installation of various groups at the 3-6-positions of the piperidine led to modest enhancement in receptor selectivity. Compounds were profiled in vivo for plasma and brain levels in order to identify candidates suitable for efficacy in a model of drug addiction. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.122

文献信息

• [EN] SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] PIPÉRIDINES/PROLINES SUBSTITUÉES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：EOLAS THERAPEUTICS INC

  公开号：WO2013119639A1

  公开（公告）日：2013-08-15

  The present invention is directed to compounds that can modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention.

  本发明涉及可以调节促觉醒素受体（如OX1或OX2，或两者）的生物活性的化合物；包括本发明化合物的药物组合物和药物组合物；用于治疗患者异常状况的方法，其中调节促觉醒素受体在医学上指示；以及本发明化合物的制备方法。
• SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Eolas Therapeutics, Inc.

  公开号：US20140364432A1

  公开（公告）日：2014-12-11

  The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX 1 or OX 2 , or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease.

  本发明涉及化合物，可以调节促觉醒肽受体（如OX1或OX2，或两者）的生物活性；涉及含有本发明化合物的药物组合物；涉及在患者中调节促觉醒肽受体是医学上指示的异常情况的治疗方法；以及涉及本发明化合物的制备方法。例如，本发明的促觉醒肽受体调节化合物可用于治疗进食障碍、肥胖症、酗酒或与酒精相关的疾病、药物滥用或成瘾（包括可卡因、鸦片类、苯丙胺或尼古丁成瘾）、睡眠障碍、精神或神经障碍中的认知功能障碍、抑郁症、焦虑症、惊恐障碍、精神分裂症、阿尔茨海默病、帕金森病、亨廷顿舞蹈病、头痛、偏头痛、疼痛、胃肠疾病、癫痫、炎症、免疫相关疾病、内分泌相关疾病、癌症、高血压、行为障碍、情绪障碍、躁郁症、痴呆症、性障碍、心理性性障碍或肾脏疾病的治疗。
• SUBSTITUTED PROLINES/PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Eolas Therapeutics Inc.

  公开号：EP2811997B1

  公开（公告）日：2018-04-11
• US9440982B2
  申请人：——

  公开号：US9440982B2

  公开（公告）日：2016-09-13
• US9499517B2
  申请人：——

  公开号：US9499517B2

  公开（公告）日：2016-11-22